Background: Finerenone is associated with a lower, yet clinically relevant, risk of hyperkalemia compared with steroidal mineralocorticoid receptor antagonists in diabetic kidney disease (DKD) trials. However, real-world data on hyperkalemia and its associated factors are lacking. Methodology: FINE-TURK is a national, observational cohort of DKD patients who were initiated on finerenone. Eligible adults were included; demographic, clinical, and laboratory data were evaluated. The primary outcome (PO) was hyperkalemia risk signal (potassium ≥ 5.0 mEq/L), and the secondary outcome (SO) was clinically meaningful hyperkalemia (potassium ≥ 5.5 mEq/L). Multivariate logistic regression (LR) was used to define features associated with both PO and SO. LR, random forest (RF), gradient boosting, and CatBoost classifiers were used to define important features associated with the PO. Results: 699 patients were included. 259 (37.1%) reached the PO, and 51 (7.3%) reached the SO. Baseline potassium and estimated glomerular filtration rate (eGFR) were the most important variables associated with both outcomes and were consistently identified as the top features across all models. Thiazide use, presence of diabetic retinopathy, and diabetes duration were also associated with the PO. LR demonstrated the highest recall; random forest achieved the highest precision in performance. Discussion: Real-world data suggest that the risk of clinically meaningful hyperkalemia is similar to that in the clinical trials. In parallel with the safety analysis of clinical trials, baseline potassium and eGFR were consistently the most important factors associated with hyperkalemia risk.
18 October 2023 in International Journal of Diabetes in Developing Countries
Toxic adenomas have traditionally been considered benign due to chronic TSH suppression, which is believed to inhibit thyroid tumorigenesis. However, emerging data challenge this dogma, reporting non-negligible malignancy rates even in toxic adenoma. This study aimed to assess thyroid cancer frequency and characteristics in surgically selected patients with toxic adenomas and to compare outcomes with propensity score–matched, surgically treated non-functioning nodules. This retrospective, cross-sectional study included 204 surgically treated patients at a tertiary referral center, comprising 102 surgically selected toxic adenomas and 102 propensity score–matched, surgically treated non-functioning nodules. Clinical, biochemical, sonographic, scintigraphic, and histopathological data were analyzed. Multivariate logistic regression analysis was used to identify independent predictors of malignancy among toxic adenomas. In this surgically selected cohort, the malignancy rate was 16.7% for toxic adenomas and 40.2% for non-functioning nodules (p < 0.001). Papillary thyroid carcinoma comprised 82.4% of all cases, making it the leading histotype (82.4%). Among toxic nodules, higher fT4/fT3 ratio (cut-off:2.58, sensitivity:93.3%, specificity:54.2%) and European Thyroid Imaging and Reporting Data System categories 4–5 were independent predictors of malignancy. No significant differences were found between groups in terms of tumor size, invasion, American Thyroid Association risk stratification, or 5-year response rates. Among surgically treated patients, the observed malignancy rate in toxic adenomas appears to be higher than traditionally expected. Elevated fT4/fT3 ratio and suspicious ultrasound features warrant closer evaluation. These findings support using ultrasound and biochemical markers in risk assessment of all thyroid nodules, regardless of functional status.
27 May 2025 in Uludağ Üniversitesi Tıp Fakültesi Dergisi
Bu çalışma, Tip 1 Diyabet (T1D) hastalarında serum magnezyum düzeylerinin glisemik kontrol ve mikrovasküler komplikasyonlarla olan ilişkisini değerlendirmeyi amaçlamaktadır. Retrospektif kesitsel olarak tasarlanan çalışmada, Temmuz 2022 - Haziran 2024 tarihleri arasında 262 T1D hastası ve 120 sağlıklı birey incelenmiştir. Çalışmanın verileri hastaların dosyalarından elde edilmiş olup, serum magnezyum düzeyleri atomik absorpsiyon spektrofotometresi kullanılarak ölçülmüştür. Magnezyum eksikliği, 1.6 mg/dL’nin altındaki serum magnezyum düzeyi olarak kabul edilmiştir. Çalışmada, T1D hastalarında kontrol grubuna göre anlamlı olarak düşük magnezyum seviyeleri tespit edilmiştir (p < 0.001). T1D hastalarının %6.1’inde (n = 16) magnezyum eksikliği saptanmıştır. Serum magnezyum düzeyi ile HbA1c arasında negatif bir korelasyon bulunmuş (r = -0.286, p < 0.001) ve magnezyum eksikliği olan hastalarda HbA1c seviyelerinin daha yüksek olduğu gözlenmiştir (p = 0.02). Bununla birlikte, mikrovasküler komplikasyonlar (retinopati, nefropati, nöropati) ile magnezyum düzeyleri arasında anlamlı bir ilişki bulunmamıştır. Bu sonuçlar, magnezyum eksikliğinin kötü glisemik kontrol ile ilişkili olabileceğini ancak mikrovasküler komplikasyonlara doğrudan etkisinin olmayabileceğini göstermektedir. Bu bulgular, glisemik profili kötü T1D hastalarında magnezyum seviyelerinin izlenmesinin kan şekeri regülasyonu açısından önemini vurgulamaktadır.